UroGen Pharma (URGN) Stock Price, Quote, News & History | Benzinga

UroGen Pharma Ltd (URGN) Stock Price, Quote, News & History

URGNNASDAQ

Trade with Public

Trade with Public

$27.60

1.003.76%

At close: Jun 4, 5:00 PM EST

$27.60

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Events Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$26.73

Close

$27.60

Volume / Avg.

329.75K / 836.44K

Day Range

$26.67 - $28.10

52 Wk Range

4.71 - 32.37

Market Cap

$1.34B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

14.17%

Days to Cover

5.82

Recent Urogen Pharma Ltd News

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week

UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.

Henry Khederian

FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.

Vandana Singh

UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.

Nabaparna Bhattacharya

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-165.74M

Investing Cash Flow (TTM)

66.83M

Financing Cash Flow (TTM)

105.09M

Free Cash Flow (TTM)

-166.04M

Capital Expenditure (TTM)

-299.00K

Net Change in Cash (TTM)

6.19M

Analyst Trends and Forecast

2

Jan

2

Mar

3

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.4

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.37B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

9.24

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-10.30%

Earnings Yield % (FWD)

-3.69%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$2.55

Company Debt

Total Debt

$189.53M

LT Debt

$189.53M

LT Debt Issuance (TTM)

$65.35M

LT Debt Repayment (TTM)

-$2.18M

Total Cash

$109.97M

Debt to Equity

-

Issuance of Debt (TTM)

$63.17M

Repayment of Debt (TTM)

-$2.18M

Key Statistics

Open

$26.73

Close

$27.60

Volume / Avg.

329.75K / 836.44K

Day Range

$26.67 - $28.10

52 Wk Range

4.71 - 32.37

Market Cap

$1.34B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

14.17%

Days to Cover

5.82

About

Sector

Health Care

Industry

Biotechnology

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy UroGen Pharma (URGN) stock?

A

You can purchase shares of UroGen Pharma (NASDAQ:URGN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are UroGen Pharma (URGN) competitors?

A

There are no as such competitors for UroGen Pharma.

Q

What is the forecast, or price target, for UroGen Pharma (URGN) stock?

A

UroGen Pharma has a consensus price target of $31.79.

Q

What is the current price for UroGen Pharma (URGN)?

A

The stock price for UroGen Pharma (NASDAQ: URGN) is $27.6 last updated June 4, 2026 at 4:00 PM EDT.

Q

Does UroGen Pharma (URGN) pay a dividend?

A

There are no upcoming dividends for UroGen Pharma.

Q

When is UroGen Pharma (NASDAQ:URGN) reporting earnings?

A

UroGen Pharma does not have any upcoming earnings scheduled.

Q

Is UroGen Pharma (URGN) going to split?

A

There is no upcoming split for UroGen Pharma.

Q

What sector and industry does UroGen Pharma (URGN) operate in?

A

UroGen Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.